Cidara Therapeutics Statistics
Share Statistics
Cidara Therapeutics has 10.95M shares outstanding. The number of shares has increased by -92.22% in one year.
| Shares Outstanding | 10.95M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0.12% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 4.66M |
| Failed to Deliver (FTD) Shares | 278 |
| FTD / Avg. Volume | 0.39% |
Short Selling Information
The latest short interest is 66.98K, so 0.95% of the outstanding shares have been sold short.
| Short Interest | 66.98K |
| Short % of Shares Out | 0.95% |
| Short % of Float | 2.23% |
| Short Ratio (days to cover) | 3.88 |
Valuation Ratios
The PE ratio is -3.03 and the forward PE ratio is -1.72.
| PE Ratio | -3.03 |
| Forward PE | -1.72 |
| PS Ratio | 1.09 |
| Forward PS | 1.7 |
| PB Ratio | -8.46 |
| P/FCF Ratio | -3.03 |
| PEG Ratio | n/a |
Enterprise Valuation
Cidara Therapeutics Inc. has an Enterprise Value (EV) of 1.36B.
| EV / Earnings | -59.2 |
| EV / Sales | 21.24 |
| EV / EBITDA | -55.71 |
| EV / EBIT | -55.44 |
| EV / FCF | -59.18 |
Financial Position
The company has a current ratio of 0.9, with a Debt / Equity ratio of 0.
| Current Ratio | 0.9 |
| Quick Ratio | 0.81 |
| Debt / Equity | 0 |
| Total Debt / Capitalization | 0 |
| Cash Flow / Debt | 0 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is 2.79% and return on capital (ROIC) is 749.03%.
| Return on Equity (ROE) | 2.79% |
| Return on Assets (ROA) | -0.34% |
| Return on Capital (ROIC) | 749.03% |
| Revenue Per Employee | 926.16K |
| Profits Per Employee | -332.33K |
| Employee Count | 69 |
| Asset Turnover | 0.95 |
| Inventory Turnover | 0.25 |
Taxes
| Income Tax | 443.00K |
| Effective Tax Rate | -0.02 |
Stock Price Statistics
The stock price has increased by 40.76% in the last 52 weeks. The beta is 0.99, so Cidara Therapeutics 's price volatility has been higher than the market average.
| Beta | 0.99 |
| 52-Week Price Change | 40.76% |
| 50-Day Moving Average | 19.84 |
| 200-Day Moving Average | 14.44 |
| Relative Strength Index (RSI) | 42 |
| Average Volume (20 Days) | 70.66K |
Income Statement
In the last 12 months, Cidara Therapeutics had revenue of 63.91M and earned -22.93M in profits. Earnings per share was -5.25.
| Revenue | 63.91M |
| Gross Profit | 62.38M |
| Operating Income | -24.48M |
| Net Income | -22.93M |
| EBITDA | -24.36M |
| EBIT | -24.48M |
| Earnings Per Share (EPS) | -5.25 |
Balance Sheet
The company has 35.78M in cash and 4.88M in debt, giving a net cash position of 30.90M.
| Cash & Cash Equivalents | 35.78M |
| Total Debt | 4.88M |
| Net Cash | 30.90M |
| Retained Earnings | -441.43M |
| Total Assets | 162.33M |
| Working Capital | 112.43M |
Cash Flow
In the last 12 months, operating cash flow was -22.43M and capital expenditures -505.00K, giving a free cash flow of -22.94M.
| Operating Cash Flow | -22.43M |
| Capital Expenditures | -505.00K |
| Free Cash Flow | -22.94M |
| FCF Per Share | -5.25 |
Margins
Gross margin is 97.62%, with operating and profit margins of -38.31% and -35.88%.
| Gross Margin | 97.62% |
| Operating Margin | -38.31% |
| Pretax Margin | -35.19% |
| Profit Margin | -35.88% |
| EBITDA Margin | -38.13% |
| EBIT Margin | -38.31% |
| FCF Margin | -35.89% |
Dividends & Yields
CDTX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -25.17% |
| FCF Yield | -10.05% |
Analyst Forecast
The average price target for CDTX is $33, which is 58.2% higher than the current price. The consensus rating is "Buy".
| Price Target | $33 |
| Price Target Difference | 58.2% |
| Analyst Consensus | Buy |
| Analyst Count | 6 |
Stock Splits
The last stock split was on Apr 24, 2024. It was a backward split with a ratio of 1:20.
| Last Split Date | Apr 24, 2024 |
| Split Type | backward |
| Split Ratio | 1:20 |
Scores
| Altman Z-Score | -2.39 |
| Piotroski F-Score | 1 |